Monitoring CD19+ B-cell depletion after rituximab infusion is commonly used to confirm pharmacodynamic activity and to rule out underdosing, especially in patients with nephrotic syndrome, where urinary loss of rituximab and altered recycling may reduce its efficacy [11-13]. This evidence concerns the gene CD19 and nephrotic syndrome.